Exelixis Inc - Company Profile
Powered by 
All the sales intelligence you need on Exelixis Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Exelixis Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Exelixis Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Exelixis Inc (Exelixis) is a biopharmaceutical company that focuses on the development and commercialization of small-molecule therapies for the treatment of cancer. The company’s marketed products include Cometriq (cabozantinib), an inhibitor of multiple receptor tyrosine kinases; Cabometyx (cabozantinib), developed for the treatment of patients with advanced renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC). These products are used by healthcare professionals to treat various types of cancer, including renal cell carcinoma and hepatocellular carcinoma. The company collaborates with partners such as Genentech, Ipsen, and Takeda for distribution and development. Exelixis is headquartered in Alameda, California, the US.
Headquarters
United States of America
Address
1851 Harbor Bay Parkway, Alameda, California, 94502
Website
www.exelixis.com
Telephone
1 302 6587581
No of Employees
1,077
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
EXEL (NASD)
Revenue (2024)
$2.3B
7%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
50.1%
(2024 vs 2023)
Market Cap*
$13.7B
Net Profit Margin (2024)
XYZ
40.3%
(2024 vs 2023)
* As of and is in US$
Exelixis Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Marketed: | Cometriq |
| Cometriq (cabozantinib) | Cabometyx |
| Cabometyx (cabozantinib) | Cotellic |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Contracts/Agreements | In May, the company partnered with Merck to supply KEYTRUDA QLEX (pembrolizumab and berahyaluronidase alfa-pmph) for subcutaneous administration, in combination with zanzalintinib, in STELLAR-316, a planned phase 3 pivotal trial in patients with resected stage II/III colorectal cancer. |
| 2026 | Contracts/Agreements | In January, the company partnered with Natera on the Exelixis-sponsored Phase 3 STELLAR-316 trial testing zanzalintinib, with or without an immune checkpoint inhibitor, in resected stage II/III colorectal cancer. |
| 2025 | Asset Purchase | In August, the company acquired the SSTR2 Program from Basecamp Bio. |
Competitor Comparison
| Key Parameters | Exelixis Inc | Eli Lilly and Co | Merck & Co Inc | Novartis AG | Sanofi |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | Switzerland | France |
| City | Alameda | Indianapolis | Rahway | Basel | Paris |
| State/Province | California | Indiana | New Jersey | Basel-Stadt | Ile-de-France |
| No. of Employees | 1,077 | 50,605 | 75,000 | 75,267 | 76,493 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Stelios Papadopoulos, Ph.D. | Chairman | Executive Board | 1994 | 77 |
| Michael M. Morrissey, Ph.D. | Director; President; Chief Executive Officer | Executive Board | 2010 | 65 |
| Christopher J. Senner | Executive Vice President; Chief Financial Officer | Senior Management | 2015 | 58 |
| Brenda J. Hefti, J.D., Ph.D. | General Counsel; Senior Vice President | Senior Management | - | 52 |
| Patrick J. Haley | Executive Vice President - Commercial | Senior Management | 2020 | 50 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer